Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Gold, Dollar Exposure Rewarded Post-Brexit

Fri, 24th Jun 2016 09:49

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday, following the UK's vote to leave the European Union.
----------
FTSE 100 - WINNERS
----------
Randgold Resources, up 15%, Fresnillo, up 11%. The miners were up on the higher gold price, quoted at USD1,311.39 an ounce compared to USD1,265.12 at the London equities close Thursday. The precious metal reached a 2016 record high earlier Friday at USD1,359.19 an ounce.

GlaxoSmithKline, up 1.1%, Mediclinic International, up 0.8%, AstraZenenca, up 0.3%. Large-cap pharmaceutical companies stand to benefit from a weak pound, as much of their revenue is in dollars and other non-UK or European currencies. Sterling was quoted at USD1.3869 at mid-morning, having touched a low it hasn't seen since 1985 at USD1.3227 earlier Friday. However, Mike Thompson, chief executive officer of the Association of the British Pharmaceutical Industry, said the UK's vote to leave the EU "creates immediate challenges" for the industry, and smaller drug shares were sharply lower, including Tiziana Life Sciences, down 19%, Evgen Pharma, down 16%, and Oxford Pharmascience Group, down 13%.
----------
FTSE 100 - LOSERS
----------
Taylor Wimpey, down 24%, Persimmon, down 24%, Barratt Developments, 21%. "The debate over what the EU referendum means for the outlook for the UK will last much longer than today, but for now we offer the conclusion that the outcome is bad for housebuilders' shares as the combination of slowing GDP, rising longer term rates and political uncertainty is like Kryptonite for that group of shares," said Liberum analyst Charlie Campbell.

Lloyds Banking Group, down 21%, Aviva, down 20%, Barclays, down 19%, Royal Bank of Scotland, down 18%. The financial services companies had been trading particularly higher in the lead up to the vote. In the week prior to the referendum the sector FTSE 350 banking index was up 12%, however on Friday morning index was down 10%.

International Consolidated Airlines Group, down 19%. The British Airways, Aer Lingus and Iberia parent company issued a profit warning for 2016 after the UK vote. "Following the outcome of the referendum, and given current market volatility, while IAG continues to expect a significant increase in operating profit this year, it no longer expects to generate an absolute operating profit increase similar to 2015," IAG said in a statement. EasyJet was down 19%.

ITV, down 18%. The broadcaster was by far the European media stock most exposed to Brexit risk, with 73% of its revenue coming from advertising, according to Societe Generale, which cut its rating on the company to Sell from Hold.
----------
FTSE 250 - WINNERS
----------
Gold miners - Acacia Mining, up 15%, Centamin, up 7.8%, Polymetal International, up 4.8%.
----------
FTSE 250 - LOSERS
----------
Banks - Aldermore Group, down 24%, Virgin Money Holdings, down 22%, Shawbrook Group, down 21%.

Housebuilders - Crest Nicholson Holdings, down 22%, Derwent London, down 22%, Bellway, down 21%, Redrow down 14%.

Recruiters - Hays, down 23%, Page Group, down 18%. Recruitment firms earlier had warned of a slow down in hiring in the run up to the referendum.
----------
MAIN MARKET AND AIM - LOSERS
----------
Proxama, down 43% at 0.429 pence. The marketing and mobile payment solutions company reported a wider pretax loss in 2015, although revenue rose, as it announced it will raise GBP2 million in a share placing. The company said its pretax loss widened to GBP6.1 million in 2015 from GBP5.9 million in 2014, despite revenue multiplying to GBP2.5 million from GBP650,978. Profit was hindered by an increase in administrative expenses to GBP8.6 million from GBP5.8 million, but revenue was boosted by good progress within the digital payments division. Proxama also said it will raise GBP2 million through the placing of 666.7 million shares at 0.3 pence each. Proxama said the placing price represents a discount of approximately 59% to the closing price of 0.725 pence on Thursday, and certain directors of the company have indicated an intention to invest GBP260,000 as part of the placing.
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
13 Oct 2022 17:55

CORRECT: Coral Products buys Ecodeck; Evgen Pharma recruits

(Correcting Harmony Energy Income Trust's use of funds.)

Read more
12 Oct 2022 21:46

TRADING UPDATES: Coral Products buys Ecodeck; Evgen Pharma recruits

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
12 Oct 2022 12:23

Evgen starts recruiting volunteers for trial of lead asset

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the start of recruitment for the pharmacokinetic and pharmacodynamic trial in healthy volunteers, and the decision to commence an investigator-sponsored clinical study for the glioblastoma programme on Wednesday.

Read more
10 Oct 2022 12:10

LONDON MARKET MIDDAY: FTSE 100 trims opening loss amid Fed hike worry

(Alliance News) - European equities traded off session lows heading into Monday afternoon, finding some poise after a poor open, as markets deal with the fallout from last week's US jobs report.

Read more
10 Oct 2022 11:00

AIM WINNERS & LOSERS: Europa Oil, i3 Energy slide as well disappoints

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
10 Oct 2022 09:58

Evgen Pharma shares jump 65% as licences SFX-01 composition for autism

(Alliance News) - Evgen Pharma PLC on Monday said it has signed a licencing deal for up to USD160.5 million with Stalicla SA for the global rights to its lead asset SFX-01 in neurodevelopmental disorders and schizophrenia.

Read more
14 Jul 2022 16:39

UK shareholder meetings calendar - next 7 days

Friday 15 July 
Aveva Group PLCAGM
DCC PLCAGM
DP Poland PLCAGM
Griffin Mining LtdAGM
MC Mining PLCGM re subscription
Monday 18 July 
Audioboom Group PLCAGM
JPMorgan European Discovery Trust PLCAGM
Tuesday 19 July 
Biotech Growth Trust PLCAGM
Clean Power Hydrogen PLCAGM
e-Therapeutics PLCAGM
Norcros PLCAGM
Ten Lifestyle Group PLCGE re commitment to sustainability, B Corp certification
Wednesday 20 July 
ADM Energy PLC AGM
Alkemy Capital Investments PLCAGM
DeepVerge PLCAGM
easyJet PLCGM re purchase of 56 Airbus A320neo family aircraft & conversion of 18 A320neo family aircraft
Fidelity China Special Situations PLCAGM
HarbourVest Global Private Equity LtdAGM
HICL Infrastructure PLCAGM
Novacyt SAAGM r
Plaza Centers NVAGM
Premier Foods PLCAGM
Royal Mail PLCAGM
Triad Group PLCAGM
Wynnstay Properties PLCAGM & GM re share buyback
Thursday 21 July  
Big Yellow Group PLCAGM
Evgen Pharma PLCAGM
Experian PLCAGM
Halma PLCAGM
Intermediate Capital Group PLCAGM
Johnson Matthey PLCAGM
Octopus AIM VCT PLCAGM
Pennon Group PLCAGM
Pires Investments PLCGM re offer from Tern PLC
QinetiQ Group PLCAGM
SSE PLCAGM
Tern PLCGM re offer for Pires Investments PLC
Vp PLCAGM
Workspace Group PLCAGM
Zephyr Energy PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
13 Jun 2022 19:22

IN BRIEF: Evgen to work with University of Michigan on asset SFX-01

Evgen Pharma PLC- Cheshire, England-based drug development company - Announces collaboration with University of Michigan, to investigate the potential anti-tumour effects of the company's lead asset SFX-01 in colorectal cancer.

Read more
8 Jun 2022 14:26

Evgen Pharma starts trial to test breast cancer tablet; loss narrows

(Alliance News) - Evgen Pharma PLC on Wednesday said it would begin a trial to test a new medicinal product later this year and said its results for the most recent financial year are in line with expectations.

Read more
25 May 2022 22:02

TRADING UPDATES: Tekcapital fundraise; Kromek wins US government order

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
18 Jan 2022 11:48

Evgen agrees fresh licensing deal with Spanish institutions

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced a memorandum of understanding with the University of Seville, Consejo Superior de Investigaciones Científicas (CSIC) and Fundación Pública Andaluza Progreso y Salud on behalf of the Institute of Biomedicine of Seville on Tuesday, for second-generation sulforaphane analogues.

Read more
18 Jan 2022 11:32

Evgen signs agreement for Spanish institutions' sulfoaphane analogues

Evgen signs agreement for Spanish institutions' sulfoaphane analogues

Read more
7 Dec 2021 21:49

EARNINGS UPDATES: Carr's beats expectations; Premier assets hit record

EARNINGS UPDATES: Carr's beats expectations; Premier assets hit record

Read more
30 Nov 2021 16:26

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
10 Nov 2021 18:22

TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up

TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.